Skip to main content
. 2022 Jul 28;19(7):e1004056. doi: 10.1371/journal.pmed.1004056

Fig 2. Excess of cases per 100,000 vaccinated in the [0–7) days risk period following BNT162b2 and mRNA-1273 vaccination in the vaccinated population aged 12–39 years from 27 December 2020 to 30 September 2021, by sex, age group, and dose (first dose blue, second dose orange).

Fig 2

*Considering the small number of cases in the vaccinated with mRNA-1273 of age 12–17 years, it was not possible to provide any estimates; excess cases are not given when the 95% CI of RI included the null effect over the [0–7) day risk interval post vaccination. RI, relative incidence; yrs, years.